Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
Dateline City:
KENILWORTH, N.J.
Presents Pivotal Data for Omarigliptin, Merck’s Investigational Once-Weekly DPP-4 Inhibitor, and Additional Data from the TECOS CV Safety Trial, at European Association for the Study of Diabetes Annual Meeting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
provided an update today on its diabetes portfolio and re-affirmed the
company’s comprehensive, long-term commitment to patients with diabetes.
Merck has a proud history in helping patients with type 2 diabetes.
Language:
English
Contact:
MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (310) 617-1067orInvestor:Justin Holko, +1 (908) 740-1879Teri Loxam, +1 (908) 740-1986
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news